Journal Article (Review Article)

DZNE-2025-01132

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Treatment for Alzheimer's disease.

Fox, N. C. ; Belder, C. ; Ballard, C. ; Kales, H. C. ; Mummery, C. ; Caramelli, P. ; Ciccarelli, O. ; Frederiksen, K. S. ; Gomez-Isla, T. ; Ismail, Z. ; Paquet, C. ; Petersen, R. C. ; Perneczky, R.DZNE* ; Robinson, L. ; Sayin, O. ; Frisoni, G. B.

2025
Elsevier London [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1016/S0140-6736(25)01329-7

Abstract: Over the last three decades, the evidence on how to best treat the cognitive and non-cognitive symptoms of patients with Alzheimer's disease has increased. Although these pharmacological and non-pharmacological strategies have significantly improved health outcomes for patients with Alzheimer's disease, many lack stringent evidence of efficacy. In this second paper of the Series, we provide practical and realistic advice on how to prioritise pharmacological and non-pharmacological strategies to ameliorate cognitive impairment and behavioural and psychological symptoms of dementia. In this clinical environment, dementia specialists are faced with the challenge of holistically integrating the much anticipated and, in some respects, controversial anti-β amyloid monoclonal antibodies. Here, we present the current approval scenario of monoclonal antibodies, our view on how they might further contribute to improve patients' quality of life, and how they could be seamlessly integrated with existing best care options.

Keyword(s): Humans (MeSH) ; Alzheimer Disease: drug therapy (MeSH) ; Alzheimer Disease: therapy (MeSH) ; Antibodies, Monoclonal: therapeutic use (MeSH) ; Quality of Life (MeSH) ; Amyloid beta-Peptides: antagonists & inhibitors (MeSH) ; Amyloid beta-Peptides: immunology (MeSH) ; Antibodies, Monoclonal, Humanized: therapeutic use (MeSH) ; Antibodies, Monoclonal ; Amyloid beta-Peptides ; Antibodies, Monoclonal, Humanized

---

Contributing Institute(s):

1. Vascular Cognitive Impairment & Post-Stroke Dementia (AG Dichgans)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2025

---

Database coverage:
; ; ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 90 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---